Research Article| Volume 149, ISSUE 1, P173-180, April 2018

Download started.


Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma

Published:February 24, 2018DOI:


      • ASRGL1 is a promising biomarker in endometrioid endometrial cancer.
      • An immunopanel consisting of p53 and ASRGL1 is a useful tool in EEC risk assessment.
      • Different EEC subgroups can be characterized using sophisticated statistical methods.



      In clinical practise, prognostication of endometrial cancer is based on clinicopathological risk factors. The use of immunohistochemistry-based markers as prognostic tools is generally not recommended and a systematic analysis of their utility as a panel is lacking. We evaluated whether an immunohistochemical marker panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological information.


      A cohort of 306 EEC specimens was profiled using tissue microarray (TMA). Cost- and time-efficient immunohistochemical analysis of well-established tissue biomarkers (ER, PR, HER2, Ki-67, MLH1 and p53) and two new biomarkers (L1CAM and ASRGL1) was carried out. Statistical modelling with embedded variable selection was applied on the staining results to identify minimal prognostic panels with maximal prognostic accuracy without compromising generalizability.


      A panel including p53 and ASRGL1 immunohistochemistry was identified as the most accurate predictor of relapse-free and disease-specific survival. Within this panel, patients were allocated into high- (5.9%), intermediate- (29.5%) and low- (64.6%) risk groups where high-risk patients had a 30-fold risk (P < 0.001) of dying of EEC compared to the low-risk group.


      P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groups with significantly different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification and guiding the allocation of treatment modalities.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Creutzberg C.L.
        • van Putten W.L.
        • Koper P.C.
        • Lybeert M.L.
        • Jobsen J.J.
        • Wárlám-Rodenhuis C.C.
        • et al.
        Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma.
        Lancet. 2000; 355: 1404-1411
        • Zeimet A.G.
        • Reimer D.
        • Huszar M.
        • Winterhoff B.
        • Puistola U.
        • Azim S.A.
        • et al.
        L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
        J. Natl. Cancer Inst. 2013; 105: 1142-1150
        • Murali R.
        • Soslow R.A.
        • Weigelt B.
        Classification of endometrial carcinoma: more than two types.
        Lancet Oncol. 2014; 15: e268-78
        • Werner H.M.
        • Salvesen H.B.
        Current status of molecular biomarkers in endometrial cancer.
        Curr. Oncol. Rep. 2014; 16: 403
        • Jongen V.
        • Briet J.
        • de Jong R.
        • ten Hoor K.
        • Boezen M.
        • van der Zee A.
        • et al.
        Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
        Gynecol. Oncol. 2009; 112: 537-542
        • Köbel M.
        • Atenafu E.G.
        • Rambau P.F.
        • Ferguson S.E.
        • Nelson G.S.
        • Ho T.C.
        • et al.
        Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: a Canadian high risk endometrial cancer consortium (CHREC) study.
        Gynecol. Oncol. 2016; 141: 559-563
        • Garg K.
        • Leitao M.M.J.
        • Wynveen C.A.
        • Sica G.L.
        • Shia J.
        • Shi W.
        • et al.
        p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes.
        Mod. Pathol. 2010; 23: 80-92
        • Nout R.A.
        • Bosse T.
        • Creutzberg C.L.
        • Jürgenliemk-Schulz I.M.
        • Jobsen J.J.
        • Lutgens L.C.
        • et al.
        Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
        Gynecol. Oncol. 2012; 126: 466-473
        • Jongen V.H.
        • Briet J.M.
        • de Jong R.A.
        • Joppe E.
        • ten Hoor K.A.
        • Boezen H.M.
        • et al.
        Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
        Int. J. Gynecol. Cancer. 2009; 19: 670-676
        • Cohn D.E.
        • Frankel W.L.
        • Resnick K.E.
        • Zanagnolo V.L.
        • Copeland L.J.
        • Hampel H.
        • et al.
        Improved survival with an intact DNA mismatch repair system in endometrial cancer.
        Obstet. Gynecol. 2006; 108: 1208-1215
        • Stefansson I.M.
        • Salvesen H.B.
        • Immervoll H.
        • Akslen L.A.
        Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
        Histopathology. 2004; 44: 472-479
        • Santin A.D.
        HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed.
        Gynecol. Oncol. 2003; 88: 263-265
        • Bosse T.
        • Nout R.A.
        • Stelloo E.
        • Dreef E.
        • Nijman H.W.
        • Jürgenliemk-Schulz I.M.
        • et al.
        L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
        Eur. J. Cancer. 2014; 50: 2602-2610
        • Pasanen A.
        • Tuomi T.
        • Isola J.
        • Staff S
        • Bützow R.
        • Loukovaara M.
        L1 cell adhesion molecule as a predictor of disease-specific survival and patterns of relapse in endometrial cancer.
        Int. J. Gynecol. Cancer. 2016; 26: 1465-1471
        • Van Gool I.C.
        • Stelloo E.
        • Nout R.A.
        • Nijman H.W.
        • Edmondson R.J.
        • Church D.N.
        • et al.
        Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
        Mod. Pathol. 2016; 29: 174-181
        • Dellinger T.H.
        • Smith D.D.
        • Ouyang C.
        • Warden C.D.
        • Williams J.C.
        • Han E.S.
        L1CAM is an independent predictor of poor survival in endometrial cancer - an analysis of the cancer genome atlas (TCGA).
        Gynecol. Oncol. 2016; 141: 336-340
        • Geels Y.P.
        • Pijnenborg J.M.
        • Gordon B.B.
        • Fogel M.
        • Altevogt P.
        • Masadah R.
        • et al.
        L1CAM expression is related to non-Endometrioid histology, and prognostic for poor outcome in Endometrioid endometrial carcinoma.
        Pathol. Oncol. Res. 2016; 22: 863-868
        • Geels Y.P.
        • van der Putten L.J.
        • van Tilborg A.A.
        • Lurkin I.
        • Zwarthoff E.C.
        • Pijnenborg J.M.
        • et al.
        Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
        Gynecol. Oncol. 2015; 137: 245-251
        • Edqvist P.H.
        • Huvila J.
        • Forsström B.
        • Talve L.
        • Carpén O.
        • Salvesen H.B.
        • et al.
        Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
        Gynecol. Oncol. 2015; 137: 529-537
        • Fonnes T.
        • Berg H.F.
        • Bredholt T.
        • Edqvist P.D.
        • Sortland K.
        • Berg A.
        • et al.
        Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
        Gynecol. Oncol. 2018; 148: 197-203
        • O'Mara T.A.
        • Zhao M.
        • Spurdle A.B.
        Meta-analysis of gene expression studies in endometrial cancer identifies gene expression profiles associated with aggressive disease and patient outcome.
        Sci. Rep. 2016; 636677
        • Cancer Genome Atlas Research Network
        • Kandoth C.
        • Schultz N.
        • Cherniack A.D.
        • Akbani R.
        • Liu Y.
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Creasman W.
        Revised FIGO staging for carcinoma of the endometrium.
        Int. J. Gynaecol. Obstet. 2009; 105: 109
        • Zaino R.J.
        • Kurman R.J.
        • Diana K.L.
        • Morrow C.P.
        The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study.
        Cancer. 1995; 75: 81-86
        • Kampf C.
        • Olsson I.
        • Ryberg U.
        • Sjostedt E.
        • Ponten F.
        Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas.
        J. Vis. Exp. 2012;
        • Uhlén M.
        • Fagerberg L.
        • Hallström B.M.
        • Lindskog C.
        • Oksvold P.
        • Mardinoglu A.
        • et al.
        Proteomics. Tissue-based map of the human proteome.
        Science. 2015; 3471260419
        • Walker R.A.
        Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment I.
        Histopathology. 2006; 49: 406-410
        • Friedman J.
        • Hastie T.
        • Tibshirani R.
        Regularization paths for generalized linear models via coordinate descent.
        J. Stat. Softw. 2010; 33: 1-22
        • Simon N.
        • Friedman J.
        • Hastie T.
        • Tibshirani R.
        Regularization paths for Cox's proportional hazards model via coordinate descent.
        J. Stat. Softw. 2011; 39: 1-13
      1. TCGA Research Network. Retrieved 30.5.2017,

        • Talhouk A.
        • McConechy M.K.
        • Leung S.
        • Yang W.
        • Lum A.
        • Senz J.
        • et al.
        Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer.
        Cancer. 2017; 123: 802-813
        • Helpman L.
        • Kupets R.
        • Covens A.
        • Saad R.S.
        • Khalifa M.A.
        • Ismiil N.
        • et al.
        Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.
        Br. J. Cancer. 2014; 110: 609-615
        • Folkins A.K.
        • Nevadunsky N.S.
        • Saleemuddin A.
        • Jarboe E.A.
        • Muto M.G.
        • Feltmate C.M.
        • et al.
        Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies.
        Mod. Pathol. 2010; 23: 1073-1079
        • Bendifallah S.
        • Canlorbe G.
        • Collinet P.
        • Arsène E.
        • Huguet F.
        • Coutant C.
        • et al.
        Just how accurate are the major risk stratification systems for early-stage endometrial cancer.
        Br. J. Cancer. 2015; 112: 793-801
        • Werner H.M.
        • Trovik J.
        • Marcickiewicz J.
        • Tingulstad S.
        • Staff AC
        • Engh M.E.
        • et al.
        A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis.
        Eur. J. Cancer. 2013; 49: 625-632
        • van der Putten L.J.
        • Visser N.C.
        • van de Vijver K.
        • Santacana M.
        • Bronsert P.
        • Bulten J.
        • et al.
        L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
        Br. J. Cancer. 2016; 115: 716-724
        • Gilks C.B.
        • Oliva E.
        • Soslow R.A.
        Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.
        Am. J. Surg. Pathol. 2013; 37: 874-881
        • Hoang L.N.
        • Kinloch M.A.
        • Leo J.M.
        • Grondin K.
        • Lee C.H.
        • Ewanowich C.
        • et al.
        Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on the cancer genome atlas (TCGA)-based molecular subgroup.
        Am. J. Surg. Pathol. 2017; 41: 245-252
        • Cantor J.R.
        • Stone E.M.
        • Chantranupong L.
        • Georgiou G.
        The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity.
        Biochemistry. 2009; 48: 11026-11031
        • Knott S.R.V.
        • Wagenblast E.
        • Khan S.
        • Kim S.Y.
        • Soto M.
        • Wagner M.
        • et al.
        Asparagine bioavailability governs metastasis in a model of breast cancer.
        Nature. 2018; 554: 378-381
        • Hussein Y.R.
        • Broaddus R.
        • Weigelt B.
        • Levine D.A.
        • Soslow R.A.
        The genomic heterogeneity of FIGO grade 3 endometrioid carcinoma impacts diagnostic accuracy and reproducibility.
        Int. J. Gynecol. Pathol. 2016; 35: 16-24
        • Talhouk A.
        • Hoang L.N.
        • McConechy M.K.
        • Nakonechny Q.
        • Leo J.
        • Cheng A.
        • et al.
        Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment.
        Gynecol. Oncol. 2016; 143: 46-53